Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Vaccine
Authors: Haiping Chen, Zhuoying Huang, Shaoying Chang, Mei Hu, Qingbin Lu, Yuntao Zhang, Hui Wang, Yanhui Xiao, Hui Wang, Yonghong Ge, Yong Zou, Fuqiang Cui, Shasha Han, Min Zhang, Shengyi Wang, Xiaoping Zhu, Biao Zhang, Zhi Li, Jia Ren, Xiao Chen, Rui Ma, Lei Zhang, Xue Guo, Linyun Luo, Xiaodong Sun, Xiaoming Yang
Institutions: China National Biotechnology (China), Shanghai Municipal Center For Disease Control Prevention, Sichuan Center for Disease Control and Prevention, Peking University, National Vaccine and Serum Institute, Chengdu Institute of Biological Products (China), Changchun Institute of Biological Products, China National Pharmaceutical Group Corporation (China)
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4288734775